A Unique Herbal Product for the Symptomatic Treatment of Over Active Bladder

Informacje na temat projektu

SAGAPROPLUS

Identyfikator umowy o grant: 782075

DOI

10.3030/782075

Projekt został zamknięty

Data podpisania przez KE 9 Sierpnia 2017

Data rozpoczęcia 1 Sierpnia 2017

Data zakończenia 30 Listopada 2017

Finansowanie w ramach

• SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy

Koszt całkowity

€ 71 429,00

Wkład UE

€ 50 000,00

Koordynowany przez

SAGAMEDICA - HEILSUJURTIR EHF
Iceland

Periodic Reporting for period 1 - SAGAPROPLUS (A Unique Herbal Product for the Symptomatic Treatment of Over Active Bladder)

Okres sprawozdawczy: 2017-08-01 do 2017-11-30

Podsumowanie kontekstu i ogólnych celów projektu

Over active bladder (OAB) is an age-related syndrome, more frequent in adults +65. It is extremely common, affecting ~500 million people and expected to keep rising due to aging of developed societies. OAB represents a human and economical burden for which no good solutions are available. OAB treatment has two lines of intervention: i) changes in lifestyle (diet, Kegel exercises) that are only partially effective and dependent on patients’ commitment, and ii) pharmacological treatment (anticholinergic drugs that inhibit contraction of bladder muscles), only partially effective and associated with multiple side effects, resulting in extremely high drop-out rates.
SagaMedica has identified the need for better treatments for OAB and has developed SagaPro+, a natural solution for dealing with OAB symptoms. SagaPro+ is made from leaves of plant Angelica Archangelica, and offers unique properties for OAB management: i) efficiency: SagaPro+ has been validated in OAB patients who reported an improvement of their symptoms, ii) safety: no side effects have been observed, iii) natural origin: SagaPro+ is 100% natural and consists only of Angelica extracts, and iv) sustainability: its harvesting and manufacturing processes have been kept local, sustainable and eco-friendly.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

We have performed a study to confirm viability of SAGAPRO+: i) technically we designed a large-scale clinical trial and defined the requirements for industrialization, ii) commercially we investigated the regulatory pathway for SagaPro+, as well as carried out a detailed study of OAB market, and iii) financially, we updated our business plan and confirmed project’s profitability.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

Economic impact: SagaPro+’s affordable price will alleviate both direct and indirect costs of OAB management to the healthcare system. Societal impact: a natural solution like SagaPro+ will alleviate the symptoms without side effects improving the quality of life of affected patients allowing them to have a normal everyday life.

image-2.png

image-1.png